133 related articles for article (PubMed ID: 15371106)
1. Development of liposomal amphotericin B dry powder inhaler formulation.
Shah SP; Misra A
Drug Deliv; 2004; 11(4):247-53. PubMed ID: 15371106
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
Pharmazie; 2004 Oct; 59(10):812-3. PubMed ID: 15544064
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance.
Shah SP; Misra A
AAPS PharmSciTech; 2004 Aug; 5(4):e65. PubMed ID: 15760062
[TBL] [Abstract][Full Text] [Related]
4. Development of liposomal salbutamol sulfate dry powder inhaler formulation.
Huang WH; Yang ZJ; Wu H; Wong YF; Zhao ZZ; Liu L
Biol Pharm Bull; 2010; 33(3):512-7. PubMed ID: 20190418
[TBL] [Abstract][Full Text] [Related]
5. Stability and transdermal absorption of topical amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Int J Pharm; 2004 Feb; 270(1-2):279-86. PubMed ID: 14726142
[TBL] [Abstract][Full Text] [Related]
6. Liposomal budesonide for dry powder inhaler: preparation and stabilization.
Joshi MR; Misra A
AAPS PharmSciTech; 2001 Nov; 2(4):25. PubMed ID: 14727862
[TBL] [Abstract][Full Text] [Related]
7. Characterization of amphotericin B liposome formulations.
Manosroi A; Kongkaneramit L; Manosroi J
Drug Dev Ind Pharm; 2004 May; 30(5):535-43. PubMed ID: 15244089
[TBL] [Abstract][Full Text] [Related]
8. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization.
Joshi M; Misra A
Int J Pharm; 2001 Jul; 223(1-2):15-27. PubMed ID: 11451628
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.
Chennakesavulu S; Mishra A; Sudheer A; Sowmya C; Suryaprakash Reddy C; Bhargav E
Asian J Pharm Sci; 2018 Jan; 13(1):91-100. PubMed ID: 32104382
[TBL] [Abstract][Full Text] [Related]
10. Liposomal dry powders as aerosols for pulmonary delivery of proteins.
Lu D; Hickey AJ
AAPS PharmSciTech; 2005 Dec; 6(4):E641-8. PubMed ID: 16408866
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
Gangadhar KN; Adhikari K; Srichana T
Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
[TBL] [Abstract][Full Text] [Related]
12. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
13. Development of liposomal amphotericin B formulation.
Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease.
Moribe K; Maruyama K
Curr Pharm Des; 2002; 8(6):441-54. PubMed ID: 12069381
[TBL] [Abstract][Full Text] [Related]
15. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
Changsan N; Chan HK; Separovic F; Srichana T
J Pharm Sci; 2009 Feb; 98(2):628-39. PubMed ID: 18484099
[TBL] [Abstract][Full Text] [Related]
17. Development and evaluation of a dry powder formulation of liposome-encapsulated oseltamivir phosphate for inhalation.
Tang Y; Zhang H; Lu X; Jiang L; Xi X; Liu J; Zhu J
Drug Deliv; 2015; 22(5):608-18. PubMed ID: 24299495
[TBL] [Abstract][Full Text] [Related]
18. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation.
Van Haute D; Jiang W; Mudalige T
Int J Pharm; 2019 Oct; 569():118603. PubMed ID: 31401296
[TBL] [Abstract][Full Text] [Related]
20. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
Stevens PJ; Lee RJ
Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
